60. 再生不良性貧血 Aplastic anemia Clinical trials / Disease details
臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166
Showing 1 to 3 of 3 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04409080 (ClinicalTrials.gov) | January 13, 2021 | 26/5/2020 | REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy REGN7257in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosup ... | A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy A Phase 1/2 Study of REGN7257(Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) ... | Severe Aplastic Anemia (SAA) | Drug: REGN7257 | Regeneron Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 57 | Phase 1/Phase 2 | United States;France;Korea, Republic of;United Kingdom |
| 2 | EUCTR2020-002031-29-FR (EUCTR) | 21/12/2020 | 10/07/2020 | REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy REGN7257in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosup ... | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY A PHASE 1/2 STUDY OF REGN7257(ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) ... | SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia apl ... | Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE ... | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;United Kingdom;Korea, Republic of | ||
| 3 | EUCTR2020-002031-29-GB (EUCTR) | 05/11/2020 | 30/06/2020 | REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy REGN7257in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosup ... | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY A PHASE 1/2 STUDY OF REGN7257(ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) ... | SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia apl ... | Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE ... | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;United Kingdom;Korea, Republic of |